Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

CEO

Employees

Country

Canada

ISIN

CA76128M1086

Listings

0 Comments

Share your thoughts

FAQ

What is Resverlogix stock price today?▼

The current price of 0VF9.LSE is C$0.12 CAD — it has increased by +0% in the past 24 hours. Watch Resverlogix stock price performance more closely on the chart.

What is Resverlogix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Resverlogix stocks are traded under the ticker 0VF9.LSE.

What is Resverlogix market cap?▼

Today Resverlogix has the market capitalization of 33M

What is Resverlogix revenue for the last year?▼

Resverlogix revenue for the last year amounts to 0 CAD.

What is Resverlogix net income for the last year?▼

0VF9.LSE net income for the last year is -21.33M CAD.

How many employees does Resverlogix have?▼

As of April 18, 2026, the company has 22 employees.

In which sector is Resverlogix located?▼

Resverlogix operates in the Energy sector.

When did Resverlogix complete a stock split?▼

Resverlogix has not had any recent stock splits.